PM Group’s U.S. expansion has been marked by steady momentum, measured investments, long-term client relationships, and deep technical credibility in pharmaceutical manufacturing. This January, that trajectory took a meaningful step forward with the appointment of Andy Rayner as President of PM Group USA, a move that underscores both continuity and ambition for the firm’s American business.
Rayner’s promotion comes at a time when PM Group is increasingly visible across key U.S. life sciences hubs, particularly Philadelphia and North Carolina, where demand for advanced pharmaceutical and biomanufacturing infrastructure continues to rise.
A leader shaped by the industry’s evolution
Rayner is no newcomer to PM Group—or to the complexities of global pharma manufacturing. Based in North Carolina, he has spent more than 35 years working with leading pharmaceutical companies on projects around the world, building a reputation as an international expert in the design of pharmaceutical manufacturing facilities. A chemical engineer by training, Rayner is a Fellow of the Institution of Chemical Engineers (IChemE), holds a master’s degree in executive leadership, and joined the PM Group board in 2018.
Most recently, he served as Executive Director and EVP for U.S. Business Development, while also holding the role of Chief Technology Officer. In those positions, Rayner was responsible for growing PM Group’s U.S. footprint and aligning the firm’s technical capabilities with evolving client needs—experience that now directly informs his mandate as President.
His appointment reflects a deliberate leadership strategy: elevating someone who understands both the engineering detail and the strategic forces reshaping pharmaceutical manufacturing, from regulatory complexity to the push for faster, more flexible facilities.
Philadelphia, North Carolina and Boston as strategic anchors
Rayner’s presidency arrives as PM Group deepens its presence in regions that are increasingly central to U.S. life sciences growth. In Greater Philadelphia, the firm expanded its U.S. footprint last year with a new Conshohocken office, supported by a $150,000 investment from the Commonwealth of Pennsylvania—a move BioBuzz previously reported on as part of the region’s broader effort to attract specialized life sciences infrastructure expertise.
Philadelphia’s mix of big pharma, CDMOs, academic research, and emerging biotech companies has made it a critical market for firms that can design and deliver complex GMP facilities. PM Group’s expansion there positions it closer to clients navigating everything from capacity expansion to next-generation manufacturing platforms.
North Carolina, meanwhile, continues to be one of the country’s most active biomanufacturing hubs, anchored by the Research Triangle and a deep workforce pipeline. Rayner’s long-standing presence in the state gives PM Group both operational continuity and local credibility as it supports projects across the Southeast and beyond.
Why this move matters
Leadership changes can sometimes feel procedural, but Rayner’s promotion signals something more strategic for PM Group USA. His combined background in technology, operations, and business development aligns closely with where the life sciences industry is headed: toward integrated solutions that shorten timelines, reduce risk, and support increasingly complex modalities.
For U.S. clients, Rayner’s appointment suggests stability paired with forward momentum—an emphasis on innovation and partnership rather than disruption for its own sake. For regional ecosystems like Philadelphia and North Carolina, it reinforces PM Group’s long-term commitment to being an active, embedded player rather than a transient service provider.
As pharmaceutical companies continue to rethink how and where they build, scale, and modernize manufacturing, leadership that understands both the technical and ecosystem-level implications becomes critical. Rayner’s elevation to President of PM Group USA places that perspective at the center of the firm’s U.S. strategy.
In that sense, this “people on the move” moment is less about a single title change and more about positioning PM Group for its next chapter—one rooted in experience, regional presence, and the evolving demands of the U.S. life sciences landscape.
